Eli Lilly and Company reports $19.8 billion revenue for quarter ended March 31, 2026, up 55.5%
Eli Lilly and Company reported revenue of $19.8 billion for the quarter ended March 31, 2026, an increase of 55.5% from the same quarter a year earlier ($12.73 billion).
For the same period it posted net income of $7.4 billion, up 168.1%, or $8.26 per diluted share (3.06 a year earlier).
That is a net margin of 37.4%.
On Sanad's AAOIFI Standard 21 screen, Eli Lilly and Company is currently compliant: interest-bearing debt is 3.7% of market capitalisation (limit 30%), and impure income is 0.2% of revenue (limit 5%).
Is Eli Lilly and Company halal?
See the full AAOIFI screening of Eli Lilly and Company
See the full AAOIFI screening of Eli Lilly and Company
Source: 10-Q filed with the U.S. Securities and Exchange Commission on April 30, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.